

Human CCL14a/HCC-1 Biotinylated Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: BAF324

DESCRIPTION		
Species Reactivity	Human	
Specificity	Detects human CCL14a/HCC-1 in ELISAs and Western blots. In sandwich immunoassays, less than 0.05% cross-reactivity with recombinant human (rh) CCL16, rhCCL8, rhCCL7, rhCCL4, and rhCCL3 is observed.	
Source	Polyclonal Goat IgG	
Purification	Antigen Affinity-purified	
Immunogen	E. coli-derived recombinant human CCL14a/HCC-1 (R&D Systems, Catalog # 324-HC) Thr20-Asn93 Accession # Q16627	
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein. See Certificate of Analysis for details.	

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Western Blot	0.1 μg/mL	Recombinant Human CCL14a/HCC-1 aa 20-93 (Catalog # 324-HC)
Human CCL14a/HCC-1 Sandwich Immunoassay		Reagent
ELISA Capture	2-8 μg/mL	Human CCL14/HCC-1/HCC-3 Antibody (Catalog # MAB3241)
ELISA Capture	2-8 μg/mL	Human CCL14/HCC-1/HCC-3 Antibody (Catalog # MAB3241R)
ELISA Detection	0.1-0.4 μg/mL	Human CCL14a/HCC-1 Biotinylated Antibody (Catalog # BAF324)
Standard		Recombinant Human CCL14a/HCC-1 aa 20-93 (Catalog # 324-HC)

PREPARATION AND STORAGE		
Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.	
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.	
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.	

BACKGROUND

HCC-1 (Hemofiltrate CC Chemokine-1) was originally isolated from the hemofiltrate of human patients with chronic renal failure (1). It belongs to the CC chemokine superfamily and has been designated CCL14a. HCC-1/CCL14a cDNA encodes a 93 amino acid (aa) residue precursor with a 19 aa signal peptide that is cleaved to form the 74 aa secreted protein (aa 20 - 93). By alternative splicing, a second longer isoform named HCC-3/CCL14b, which includes sequences from exon 3, also exists (2). HCC-1/CCL14a is expressed constitutively in various normal tissues including spleen, liver, muscle, gut and bone marrow. It circulates at nanomolar concentrations in human plasma. Different post-translationally modified HCC-1/CCL14a, including O-glycosylated and N-terminally truncated variants of HCC-1/CCL14a, have been identified (3, 4). Whereas the 74 aa peptide is a weak CCR1 agonist, the proteolytically processed, truncated HCC-1/CCL14a (aa 28 - 93) is a highly potent agonist of CCR1, CCR5 and to a lesser extent, CCR3. HCC-1/CCL14a (aa 28 - 93) promotes chemotaxis of T lymphocytes, monocytes and eosinophils, and inhibits infection of M-tropic human immunodeficiency virus type 1. Activation of the HCC-1/CCL14a precursor to active peptide is mediated by the urokinase type plasminogen activator or plasmin (5).

References:

- 1. Schulz-Knappe, P. et al. (1996) J. Exp. Med. 183:295.
- Forssmanns, U. et al. (2001) J. Leukocyte Biology 70:357.
- 3. Richter, R. et al. (2000) Biochemistry 39:10799.
- 4. Munch, J. et al. (2002) Antimicrob. Agents Chemother. 46:982.
- 5. Vakili, J. et al. (2001) J. Immunol. 167:3406.

